Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation - PubMed (original) (raw)
Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation
Cristian Tomasetti et al. Proc Natl Acad Sci U S A. 2013.
Abstract
Although it has been hypothesized that some of the somatic mutations found in tumors may occur before tumor initiation, there is little experimental or conceptual data on this topic. To gain insights into this fundamental issue, we formulated a mathematical model for the evolution of somatic mutations in which all relevant phases of a tissue's history are considered. The model makes the prediction, validated by our empirical findings, that the number of somatic mutations in tumors of self-renewing tissues is positively correlated with the age of the patient at diagnosis. Importantly, our analysis indicates that half or more of the somatic mutations in certain tumors of self-renewing tissues occur before the onset of neoplasia. The model also provides a unique way to estimate the in vivo tissue-specific somatic mutation rates in normal tissues directly from the sequencing data of tumors. Our results have substantial implications for the interpretation of the large number of genome-wide cancer studies now being undertaken.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1.
The “Fish,” a schematic representation of the different phases in which somatic mutations occur in a tissue giving rise to a cancer. Starting from a single precursor cell, a tissue is created via clonal expansion (head of the fish). The tissue is then subjected to periodic self-renewals (body of the fish). During development and tissue renewal, passenger mutations occur randomly, undergo clonal expansions (various brown clones), and either go extinct or expand as successive passenger mutations accumulate. A driver gene mutation can initiate a tumor cell clone, which then can expand through subsequent driver mutations, eventually yielding a clinically detectable tumor mass (fish’s tail, where each clonal expansion driver by a new driver mutation is indicated by a different color). Passenger mutations occur during this phase as well.
Fig. 2.
Relationship between the number of somatic mutations and the age of diagnosis in four types of cancer: chronic lymphocitic leukemia (A), uterine cancer (B), colorectal cancer (C), and pancreatic cancer (D).
Similar articles
- Stochastic modeling indicates that aging and somatic evolution in the hematopoetic system are driven by non-cell-autonomous processes.
Rozhok AI, Salstrom JL, DeGregori J. Rozhok AI, et al. Aging (Albany NY). 2014 Dec;6(12):1033-48. doi: 10.18632/aging.100707. Aging (Albany NY). 2014. PMID: 25564763 Free PMC article. - Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer.
Gatenby RA, Brown J. Gatenby RA, et al. Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):162-166. doi: 10.1016/j.bbcan.2017.03.005. Epub 2017 Mar 21. Biochim Biophys Acta Rev Cancer. 2017. PMID: 28341421 Free PMC article. Review. - Mathematical models of tissue stem and transit target cell divisions and the risk of radiation- or smoking-associated cancer.
Little MP, Hendry JH. Little MP, et al. PLoS Comput Biol. 2017 Feb 14;13(2):e1005391. doi: 10.1371/journal.pcbi.1005391. eCollection 2017 Feb. PLoS Comput Biol. 2017. PMID: 28196079 Free PMC article.
Cited by
- Deletions Rate-Limit Breast and Ovarian Cancer Initiation.
Houlahan KE, Bihie M, Contreras JG, Fulop DJ, Lopez G, Huang HH, Van Loo P, Curtis C, Boutros PC, Huang KL. Houlahan KE, et al. bioRxiv [Preprint]. 2024 Oct 21:2024.10.17.618945. doi: 10.1101/2024.10.17.618945. bioRxiv. 2024. PMID: 39484366 Free PMC article. Preprint. - When Do Tumours Develop? Neoplastic Processes Across Different Timescales: Age, Season and Round the Circadian Clock.
Bieuville M, Dujon AM, Raven N, Ujvari B, Pujol P, Eslami-S Z, Alix Panabières C, Capp JP, Thomas F. Bieuville M, et al. Evol Appl. 2024 Oct 22;17(10):e70024. doi: 10.1111/eva.70024. eCollection 2024 Oct. Evol Appl. 2024. PMID: 39444444 Free PMC article. Review. - Tumour mutational burden: clinical utility, challenges and emerging improvements.
Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altbürger C, Schwab C, Allgäuer M, Ahadova A, Kloor M, Schirmacher P, Peters S, Krämer A, Christopoulos P, Stenzinger A. Budczies J, et al. Nat Rev Clin Oncol. 2024 Oct;21(10):725-742. doi: 10.1038/s41571-024-00932-9. Epub 2024 Aug 27. Nat Rev Clin Oncol. 2024. PMID: 39192001 Review. - CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers.
Teh SSK, Bowland K, Halper-Stromberg E, Kotwal A, Bennett A, Skaist A, Tang J, Cai F, Macoretta A, Liang H, Kamiyama H, Wheelan S, Lin MT, Hruban RH, Hung CF, Goldstein M, Scharpf RB, Roberts NJ, Eshleman JR. Teh SSK, et al. NAR Cancer. 2024 Jun 19;6(2):zcae028. doi: 10.1093/narcan/zcae028. eCollection 2024 Jun. NAR Cancer. 2024. PMID: 38915758 Free PMC article. - An improved epigenetic counter to track mitotic age in normal and precancerous tissues.
Zhu T, Tong H, Du Z, Beck S, Teschendorff AE. Zhu T, et al. Nat Commun. 2024 May 17;15(1):4211. doi: 10.1038/s41467-024-48649-8. Nat Commun. 2024. PMID: 38760334 Free PMC article.
References
- van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009;71:241–260. - PubMed
Publication types
MeSH terms
Grants and funding
- R37 CA043460/CA/NCI NIH HHS/United States
- T32 CA009337/CA/NCI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- 5P30 CA006516-46/CA/NCI NIH HHS/United States
- P30 CA006516/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources